Recent Updates
Recently added Catalysts
ORGO Negative Sentiment Score: 20/100

Organogenesis Holdings, Inc. Investigated by the Portnoy Law Firm

Key Takeaway: Organogenesis Holdings, Inc. is under investigation by the Portnoy Law Firm for potential securities fraud following a significant drop in stock price. This decline, amounting to 10.14%, was prompted by a regulatory change announced by the Centers for Medicare & Medicaid Services affecting skin substitute grafts and related products. Analysts noted that the absence of key Local Coverage Determinations has intensified competition in an already crowded market, undermining investor confidence and projecting a concerning outlook for future revenues. The law firm is encouraging affected investors to reach out for legal recourse.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investigation initiated into possible securities fraud.
  • Stock price plummeted 10.14% following a negative regulatory announcement.
  • Loss of key regulatory barriers leaving the company vulnerable to more competition.
  • Investor confidence significantly eroded due to market adjustments and future revenue threats.

Full Press Release Details

LOS ANGELES, April 15, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Organogenesis Holdings, Inc. (“Organogenesis" or the "Company") (NASDAQ: ORGO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via http://portnoylaw.com/organogenesis-holdings-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
Organogenesis’s stock price plummeted $0.59 per share, or 10.14%, to close at $5.28 per share on December 30, 2025, thereby injuring investors. This sharp market contraction was triggered by a December 26, 2025, announcement from the Centers for Medicare & Medicaid Services (CMS) regarding a significant shift in the regulatory environment for specialized medical products. The primary driver of the valuation collapse was the disclosure that the agency had withdrawn final Local Coverage Determinations (LCDs) for skin substitute grafts and cellular and tissue-based products that were scheduled for implementation the following year.
The decline was further exacerbated by the immediate competitive implications of this policy reversal. Analysts observed that the removal of these specific LCDs would leave the Company vulnerable to a significantly more crowded marketplace, as Organogenesis would now "face increased competition from over 300 other market participants." The revelation that the Company had lost a key regulatory barrier to entry led to an immediate loss of investor confidence and a rapid erosion of shareholder value as the market adjusted to the heightened threat to Organogenesis’s market share and the potential for a material decline in its future revenue.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
Attorney Advertising

Tags

Frequently Asked Questions

What is the investigation by Portnoy Law Firm about?

The Portnoy Law Firm is investigating Organogenesis Holdings for potential securities fraud.

Why did Organogenesis’s stock price drop?

The stock price fell due to a major regulatory shift announced by CMS on December 26, 2025.

How can investors contact Portnoy Law Firm?

Investors can reach attorney Lesley F. Portnoy at 310-692-8883 or lesley@portnoylaw.com.

What happened on December 30, 2025, with Organogenesis's stock?

On that date, the stock fell 10.14%, closing at $5.28 per share due to investor panic.

What were the consequences of CMS's announcement?

The announcement removed key regulatory protections, increasing competition for Organogenesis.

Last updated: Apr 15, 2026